A plasmapheresis system and a method for operating a plasmapheresis system are provided by which the volume/weight of anticoagulated plasma that is collected is optimized. In one example, a nomogram is provided that utilizes the donor's hematocrit to calculate the volume/weight of raw plasma within a plasma product having the maximum volume permitted by the FDA nomogram. In a plasmapheresis procedure having multiple collection phases followed by a reinfusion cycle in which concentrated red blood cells are returned to the donor, the volume of plasma product to be collected is calculated prior to the start of each collection cycle to account for the donor's increasing hematocrit, thus resulting in a greater total volume of plasma product to be collected during the plasmapheresis procedure.

A plasmapheresis system and a method for operating a plasmapheresis system are provided by which the volume/weight of anticoagulated plasma that is collected is optimized. In one example, a nomogram is provided that utilizes the donor's hematocrit to calculate the volume/weight of raw plasma within a plasma product having the maximum volume permitted by the FDA nomogram. In a plasmapheresis procedure having multiple collection phases followed by a reinfusion cycle in which concentrated red blood cells are returned to the donor, the volume of plasma product to be collected is calculated prior to the start of each collection cycle to account for the donor's increasing hematocrit, thus resulting in a greater total volume of plasma product to be collected during the plasmapheresis procedure.

Systems and methods are provided for depleting platelets from blood. The system includes a multi-stage blood separation chamber in which blood is separated into red blood cells and platelet-rich plasma. The platelet-rich plasma is conveyed from a first stage of the chamber to a second stage, where it is separated into platelets and platelet-poor plasma. The platelet-poor plasma is conveyed out of the chamber while the platelets are allowed to accumulate in the second stage of the chamber. When a controller of the system has determined that the maximum chamber capacity of platelets has been accumulated in the second stage of the chamber, the platelets are conveyed out of the chamber to a waste container. The cycle of separating blood into its components, accumulating platelets in the chamber, and then flushing the platelets from the chamber is repeated until a target platelet concentration of the blood is achieved.

A blood processing system for collecting plasma reduced platelets and anticipating plasma return includes a venous access device, a blood component separation device, a first return line, a recirculation line, and a second return line. The venous access device draws whole blood from a subject and returns blood components to the subject using a first pump. The blood component separation device separates the drawn blood into a first blood component and a second blood component, and sends the first blood component to a first blood component bag. The first return line fluidly connects the venous-access device and the blood component separation device. The recirculation line connects the first blood component container and the separation device. The second return line fluidly connects the first blood component container and the first return line and is configured to return the first blood component within the first blood container to the subject.

A centrifugal separation device of a blood component collection system, which is one form of a biological component collection system, performs a pressure release step of stopping a collection and returning pump at the end of a returning operation, and releasing a positive pressure inside a filter structural member, a clamp closure step of closing an inlet flow passage and an outlet flow passage of the filter structural member, and a collection operation starting step of starting a subsequent collection operation.

A washed platelet having a sufficiently low blood plasma content rate is more securely and efficiently obtained.

A tertiary separator (42) includes a main body (58) which has a third chamber (52) and is formed as an accommodating portion (54a) accommodating a centrifuged platelet (104), an inlet (77c) which allows a platelet containing component (100) and a platelet added solution (102) to flow in, and an outlet (78a) which allows blood plasma, the platelet added solution (102), and the platelet (104) to flow out. A bottom portion (first bottom portion (60)) of at least a portion forming the accommodating portion (54a) in a wall portion included in the main body (58) is formed of a soft material.

A plasmapheresis system and a method for operating a plasmapheresis system are provided by which the volume/weight of anticoagulated plasma that is collected is optimized. In one example, a nomogram is provided that utilizes the donor's hematocrit to calculate the volume/weight of raw plasma within a plasma product having the maximum volume permitted by the FDA nomogram. In a plasmapheresis procedure having multiple collection phases followed by a reinfusion cycle in which concentrated red blood cells are returned to the donor, the volume of plasma product to be collected is calculated prior to the start of each collection cycle to account for the donor's increasing hematocrit, thus resulting in a greater total volume of plasma product to be collected during the plasmapheresis procedure.

Provided are methods, systems and compositions for the preparation of platelets, including improved methods and systems for preparing apheresis derived platelet units suitable for infusion and compositions comprising such platelet units.

A system for collecting MNCs to be treated with irradiation comprises a fluid circuit comprising a product container for receiving a MNC product. The system comprises a separator to work in association with the fluid circuit, the separator comprising a chamber for separation into RBCs, plasma, and an interface carrying MNCs between the RBCs and the plasma. A microprocessor-based controller is in communication with the separator, wherein the controller receives input of a target hematocrit for the MNC product. The controller also receives input for a total volume of whole blood and a number of cycles, and directs the interface and a portion of the RBCs into the product container for a resulting product volume comprising a volume of MNCs and a volume of RBCs. The controller automatically adjusts a RBC volume so that a ratio of RBCs within the MNC product to MNC product equals the target hematocrit.

The present disclosure relates to methods and apparatus for producing platelet rich plasma, bone marrow mononuclear cells, stromal vascular fraction from adipose tissue, and other concentrated or enriched biological fluids.